Pre-Made Opinercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-938

Pre-Made Opinercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Opinercept is a tumor necrosis factor receptor superfamily protein TNFRSF1B (human extracellular domain fragment) fusion protein with immunoglobulin G1 (human FC fragment) that sequesters extracellular TNF-α to decrease signal transduction, which has been used for the rheumatoid arthritis treatment.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-938-1mg 1mg 3090
GMP-Bios-INN-938-10mg 10mg Inquiry
GMP-Bios-INN-938-100mg 100mg Inquiry
GMP-Bios-INN-938-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Opinercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F
INN Name Opinercept
TargetTNF
FormatFusion Protein
Derivationhuman
Species Reactivityhuman
CH1 IsotypeFusion - [TNFRSF1B (tumor necrosis factor receptor (TNFR) superfamily member 1B, TNFBR, p75, CD120b)]2 - IGHG1 Fc (Fragment constant)
VD LCFusion - [TNFRSF1B (tumor necrosis factor receptor (TNFR) superfamily member 1B, TNFBR, p75, CD120b)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesMycenax Biotech Inc. (Miaoli Taiwan)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0